UPCC 31218: A prospective multicentre randomised controlled study evaluating SIR-Spheres Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic CholangioCArcinoma (SIRCCA)
Enrolling By Invitation
99 years or below
All
5 participants needed
1 Location
Brief description of study
The main purpose of this research study is to find out whether Selective Internal Radiation Therapy (SIRT) preceding a standard chemotherapy treatment can improve survival in patients with cholangiocarcinoma in the liver, compared to chemotherapy alone.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: unresectable intrahepatic CholangioCArcinoma, SIRCCA
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 831772
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
